Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetuzumab vs Glucocorticoids in Active Moderate to Severe TAO
NCT07152340Phase 4Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of sycume in thyroid associated ophthalmopathy (TAO), sponsored by Shanghai Changzheng Hospital. Started Apr 2025; status: recruiting.
02
Drugs
sycume
03
Conditions
thyroid associated ophthalmopathy (TAO)
Beyond the preview
Go deeper on NCT07152340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07152340.